Lizinimazole hydrochloride powder was once a broad-spectrum deworming drug, mainly targeting gastrointestinal and pulmonary nematodes in livestock and poultry. It works by irreversibly inhibiting the succinate reductase in the parasite, causing the parasite's energy metabolism to fail and leading to death. This drug has also been found to have significant immunomodulatory functions, capable of restoring the activity of damaged T lymphocytes, macrophages, and granulocytes, and enhancing the body's disease resistance. However, due to the possibility of severe immune system adverse reactions such as severe granulocytopenia during clinical use, as well as the risk of neurotoxicity, most countries have strictly limited its veterinary and human use indications. Currently, it is mainly used as a laboratory research reagent for exploring immune mechanisms, highlighting the typical life cycle of the drug from widespread application to strict control.
|
|
|
|
|
|
|
|
Pharmacological Mechanism
Antiparasitic Effect
Levamisole hydrochloride exerts its effect by selectively inhibiting succinate dehydrogenase in the muscle cells of parasites, blocking the process of fumarate converting to succinate, interfering with the parasite's anaerobic metabolism and reducing energy production. After the parasite comes into contact with the drug, depolarization of the nerve and muscle leads to continuous contraction, eventually causing paralysis and death. Its cholinergic-like effect promotes the expulsion of the parasite, showing significant efficacy against infections caused by roundworms, hookworms, pinworms, and enterobiasis. The single-dose clearance rate of parasite eggs is relatively high, making it particularly suitable for group treatment.
Immunomodulatory effect
Levamisole hydrochloride has a bidirectional immunomodulatory function:
Enhancing immune response: Activating macrophages and T lymphocytes, promoting interferon production, and enhancing cellular immunity. Clinically used for recurrent respiratory infections and as an adjuvant treatment after tumor surgery (such as colorectal cancer, melanoma), it can reduce the recurrence rate.
Regulating autoimmunity: By balancing Th1/Th2 cells, alleviating inflammatory reactions in rheumatoid arthritis and systemic lupus erythematosus, often used in combination with glucocorticoids to reduce the dosage.
Clinical Application and Dosage
Antiparasitic treatment
Roundworm infection: 1.5-2.5mg/kg for adults, taken on an empty stomach or before bedtime; for children, 2-3mg/kg.
Hookworm infection: 1.5-2.5mg/kg, once daily, for 3 consecutive days.
Filariasis: 4-6mg/kg, taken in 2-3 divided doses, for 3 consecutive days.
Mixed infection: Combined with thiabendazole and thiabendazole can enhance the therapeutic effect.
Auxiliary treatment for immune-related diseases
After tumor surgery: Sequential use with chemotherapy drugs to enhance anti-tumor immune response, monitoring bone marrow suppression is necessary.
Autoimmune diseases: Combined with glucocorticoids, regular liver function checks are required. Discontinue medication if skin rash or joint pain worsens.
Viral diseases: Such as stubborn oral ulcers and herpes zoster, combined with antiviral drugs.
Adverse Reactions and Contraindications
Common adverse reactions
Gastrointestinal reactions: Nausea, vomiting, abdominal pain (occurrence rate about 10%-20%), mostly transient.
Neurological symptoms: Dizziness, headache, fatigue, occasionally ataxia or blurred vision.
Allergic reactions: Rash, itching, photosensitive dermatitis, severe cases may present with immediate or Arthus-type allergic reactions.
Blood system abnormalities: Granulocyte reduction (often reversible), thrombocytopenia, higher risk in patients with rheumatic diseases or tumors.
Liver function damage: Elevated transaminases, long-term use requires monitoring of liver function.
Contraindications and Precautions
Absolute contraindications: Liver and kidney dysfunction, active hepatitis, early pregnancy, patients with existing schistosomiasis.
Cautionary populations:
Patients with rheumatoid arthritis: Prone to inducing agranulocytosis.
Patients with Sjogren's syndrome: May aggravate symptoms.
Children: Strictly calculate the dosage based on body weight, avoid accidental ingestion.
Drug interactions:
Combined with ethambutol for filariasis infection can treat.
Avoid using with tetrachloroethylene to prevent increased toxicity.
Safety and Risk Control
Toxicity studies
Animal experiments show that the LD₅₀ (half lethal dose) of levamisole hydrochloride varies depending on the route of administration. Oral toxicity is lower, but excessive use may lead to M-cholinergic effects (such as salivation, diarrhea, bronchospasm) and N-cholinergic effects (such as muscle tremors, respiratory paralysis). Poisoning treatment requires the use of atropine to counteract M-cholinergic symptoms and is supplemented with cardiotonic and diuretic therapy.
Risk Control Measures
Dose Individualization: Adjust the dosage based on the type of infection, weight, and age to avoid overdose.
Medication Monitoring: Regularly check blood routine and liver function during treatment, especially when using for a long term or in combination with other drugs.
Patient Education: Inform patients of possible adverse reactions and seek medical attention immediately if severe symptoms occur (such as convulsions, jaundice).
Special Population Management: Pregnant women and lactating women are prohibited from using; children need to be administered medication under the supervision of adults.
Immunosuppressive effect
Levamisole hydrochloride mainly exerts an immunomodulatory effect rather than a direct immunosuppressive effect. Its core mechanism is to restore or enhance immune function by activating immune cells and strengthening immune responses. It only indirectly alleviates inflammatory reactions in specific autoimmune diseases by regulating abnormal immune responses. The following is a detailed analysis:
The immunomodulatory effect of levamisole hydrochloride is bidirectional. The core mechanism is to restore or enhance the immune function by activating immune cells and strengthening the immune response, rather than directly suppressing the immune system. Specifically, it manifests as:
Activating immune cells: Levamisole hydrochloride can induce the early pre-immune T cells to differentiate into mature functional T cells, while activating macrophages and granulocyte migration inhibitory factor, enhancing their phagocytic function. This effect is particularly significant in individuals with impaired immune function (such as patients with recurrent infections), and can restore the suppressed immune function.
Promoting cytokine secretion: Levamisole hydrochloride can stimulate the proliferation of bone marrow hematopoietic stem cells and promote the secretion of cytokines such as interleukin-2 (IL-2) and interferon-γ (IFN-γ). These cytokines are key regulators of the immune response and can enhance the activity of cellular immunity and humoral immunity.
Regulating abnormal immune responses: In autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus), levamisole hydrochloride reduces inflammatory responses and tissue damage by inhibiting the immune response mediated by overactive T cells. For example, it can regulate the Th1/Th2 cell balance and reduce the production of autoantibodies, thereby alleviating the disease activity.
Enhancing anti-tumor immunity: In post-tumor adjuvant therapy, levamisole hydrochloride enhances the immune recognition and attack ability of the body against tumor cells, reducing the recurrence probability. Its mechanism may be related to promoting the maturation of dendritic cells and activating natural killer cells (NK cells).
It should be noted that the immunomodulatory effect of levamisole hydrochloride is selective:
For individuals with weakened immunity: such as patients with recurrent respiratory infections, levamisole hydrochloride can significantly enhance immune function and improve resistance.
For patients with autoimmune diseases: such as patients with rheumatoid arthritis, it regulates abnormal immune responses to reduce inflammation, rather than completely suppressing the immune system.
For individuals with normal immunity: levamisole hydrochloride has no significant immune enhancement effect. Long-term and high-dose use may lead to adverse reactions such as granulocyte reduction due to excessive activation of immune cells.
Summary and Outlook
Levamisole hydrochloride, as a classic antiparasitic drug, has a significant role in deworming treatment due to its high efficacy and low toxicity. Additionally, its immunomodulatory effect provides new ideas for tumor adjunctive therapy and autoimmune disease management. However, adverse reactions (especially hematological toxicity) and drug interactions require clinical attention. Future research could focus on:
Develop new derivatives to further reduce toxicity;
Explore combined medication regimens for its use in immunotherapy;
Strengthen safety studies for specific populations (such as children and the elderly).